Company Profile
Corvus Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- CRVS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
13.86 USD (-0.50%)
Close
Last updated: August 6, 2026
983M USD
Market cap
Why the stock is moving
The latest monitored company update is “Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.
Company overview
ITK Inhibition
Corvus Pharmaceuticals develops therapies based on inhibition of interleukin-2-inducible T-cell kinase, or ITK. The approach is intended to rebalance immune-cell activity in inflammatory diseases and cancer.
Soquelitinib
Soquelitinib is an oral, selective ITK inhibitor. Its lead immunology program is a Phase 2 study in moderate-to-severe atopic dermatitis, supported by Phase 1 evidence of clinical activity and post-treatment responses.
Oncology Applications
Corvus is also evaluating ITK biology in oncology, where modulating T-cell differentiation and function may provide a distinct immunotherapeutic mechanism.
Future catalysts
Final Phase 1 atopic-dermatitis data for soquelitinib at the SID Annual Meeting in May 2026.
Recent news
- 01
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results
Source: Corvus Pharmaceuticals
- 02
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
Source: Corvus Pharmaceuticals
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Corvus Pharmaceuticals (CRVS)?
Corvus Pharmaceuticals (CRVS) most recently closed at 13.86 USD, a -0.50% move versus the previous session.
What is the market cap of Corvus Pharmaceuticals (CRVS)?
Corvus Pharmaceuticals currently has a market capitalization of 983M USD on BioPharmSignal.
What does Corvus Pharmaceuticals do?
ITK Inhibition Corvus Pharmaceuticals develops therapies based on inhibition of interleukin-2-inducible T-cell kinase, or ITK. The approach is intended to rebalance immune-cell activity in inflammatory diseases and cancer. Soquelitinib Soquelitinib is an oral, selective ITK inhibitor. Its lead immunology program is a Phase 2 study in moderate-to-severe...
On which exchange is CRVS stock listed?
Corvus Pharmaceuticals (CRVS) is associated with NASDAQ, United States, Biopharma.
What is soquelitinib?
Final Phase 1 atopic-dermatitis data for soquelitinib at the SID Annual Meeting in May 2026.
Which conditions is Corvus Pharmaceuticals targeting with soquelitinib?
Corvus Pharmaceuticals is associated with oncology, cancer therapeutics, immunology based on its company overview and current catalyst commentary.
How does Corvus Pharmaceuticals describe recent progress with soquelitinib?
Final Phase 1 atopic-dermatitis data for soquelitinib at the SID Annual Meeting in May 2026.
What is Inhibition?
ITK Inhibition Corvus Pharmaceuticals develops therapies based on inhibition of interleukin-2-inducible T-cell kinase, or ITK.